What question did this study set out to answer?

Identify a multi-gene progressive biomarker panel with causal genetic support to track islet molecular changes across normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes.

August 20, 2026BiomedicinesOpen Access

Identification of Progressive Islet Biomarkers for Type 2 Diabetes by Integrated Transcriptomics and Mendelian Randomization: Alterations Spanning the Normal Glucose Tolerance–Impaired Glucose Tolerance–Type 2 Diabetes Continuum

View Full Paper

Ask AI

Bookmark

Identify a multi-gene progressive biomarker panel with causal genetic support to track islet molecular changes across normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes.
Integrated two human islet transcriptomic datasets (n = 181: 50 NGT, 56 IGT, 75 T2D) using WGCNA, differential expression, and a five-algorithm machine learning consensus.
Assessed progressive expression via Jonckheere–Terpstra trend testing, evaluated causality with two-sample Mendelian randomization and Bayesian colocalization, and validated cell-type patterns using single-cell RNA sequencing (127,919 cells).
Identified a 12-gene panel passing Bonferroni-corrected trend testing (p ≤ 2.4 × 10⁻³), with KCNE4 displaying early prediabetic alterations reaching 94.0% of its diabetes-stage effect size (nominal p = 1.75 × 10⁻⁴).
Two-sample Mendelian randomization showed protective associations for MYOF (OR 0.999, FDR = 1.68 × 10⁻⁴) and RUNX2 (OR 0.998, FDR = 1.68 × 10⁻⁴), though Bayesian colocalization supported linkage disequilibrium over shared causal variants (PP.H4 < 0.001).
The diagnostic model achieved a bootstrap-corrected AUC of 0.833, while single-cell analysis confirmed upregulation of 7 hub genes in β-cells and progressive α-cell expansion from 28.97% to 46.41%.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Multi-omics study uncovers a 12-gene progressive islet biomarker panel across the prediabetes-to-diabetes continuum, highlighting KCNE4 as an early-warning marker for type 2 diabetes.

Cite This Study

Aisikaer et al. (2026) studied this question.

synapsesocial.com/papers/6a86b5da8a91293e6a1cd712 https://doi.org/10.3390/biomedicines14081850

View Full Paper

Ask AI

Bookmark

Implication

Multi-omics study uncovers a 12-gene progressive islet biomarker panel across the prediabetes-to-diabetes continuum, highlighting KCNE4 as an early-warning marker for type 2 diabetes.

Identification of Progressive Islet Biomarkers for Type 2 Diabetes by Integrated Transcriptomics and Mendelian Randomization: Alterations Spanning the Normal Glucose Tolerance–Impaired Glucose Tolerance–Type 2 Diabetes Continuum

Key Points

Discussion

Implication

Cite This Study

Identification of Progressive Islet Biomarkers for Type 2 Diabetes by Integrated Transcriptomics and Mendelian Randomization: Alterations Spanning the Normal Glucose Tolerance–Impaired Glucose Tolerance–Type 2 Diabetes Continuum

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider